BUZZ-PREVIEW-India's Dr Reddy's falls ahead of Q3 results

** Dr Reddy's Laboratories REDY.NS drops ~1% to 1,281.90 rupees ahead of Q3 results

** Drugmaker had reported 9.5% drop in Q2 profit, while rev grew ~17%

** On avg, analysts see REDY's Q3 consol net profit growing ~8% y/y and rev rising 12%, per data compiled by LSEG

** Expects "subdued" U.S. sales growth on lower sales of cancer drug gRevlimid

** However, BNP Paribas says gains from nicotine replacement therapy, which REDY bought from Haleon HLN.L for $633 mln in 2024, will help rev

** Centrum says sales of vaccines that co acquired via partnership with French drugmaker Sanofi's SASY.PA Indian unit last year will help India rev

** Rivals Cipla CIPL.NS and Sun Pharma SUN.NS will report Q3 results next week

** REDY's ~20% YTD climb in 2024 was the smallest vs CIPL's ~23% rise and SUN's ~50% jump